Bayer/J&J Attempt At New Lands For Xarelto Backfires With MAGELLAN
This article was originally published in The Pink Sheet Daily
Ability of novel anticoagulants to capture an extra indication in acutely ill patients currently treated with blockbuster Lovenox is now in doubt.
You may also be interested in...
Simultaneously, partner Bayer submits applications in Europe, where rivaroxaban already is approved, for those indications and one more.
The APPRAISE-2 trial was stopped due to excess bleeding. But the study tested the drug as an add-on treatment in a high-risk population and in a marginal indication for the anticoagulant.
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.